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A surveillance program (SENTRY) of bloodstream infections (BSI) in the United States, Canada, Latin
America, and Europe from 1997 through 1999 detected 1,184 episodes of candidemia in 71 medical centers (32
in the United States, 23 in Europe, 9 in Latin America, and 7 in Canada). Overall, 55% of the yeast BSIs were
due to Candida albicans, followed by Candida glabrata and Candida parapsilosis (15%), Candida tropicalis (9%),
and miscellaneous Candida spp. (6%). In the United States, 45% of candidemias were due to non-C. albicans
species. C. glabrata (21%) was the most common non-C. albicans species in the United States, and the propor-
tion of non-C. albicans BSIs was highest in Latin America (55%). C. albicans accounted for 60% of BSI in Canada
and 58% in Europe. C. parapsilosis was the most common non-C. albicans species in Latin America (25%), Can-
ada (16%), and Europe (17%). Isolates of C. albicans, C. parapsilosis, and C. tropicalis were all highly susceptible
to fluconazole (97 to 100% at <8 g/ml). Likewise, 97 to 100% of these species were inhibited by <1 g/ml of
ravuconazole (concentration at which 50% were inhibited [MIC50], 0.007 to 0.03 g/ml) or voriconazole (MIC50,
0.007 to 0.06 g/ml). Both ravuconazole and voriconazole were significantly more active than fluconazole against
C. glabrata (MIC90s of 0.5 to 1.0 g/ml versus 16 to 32 g/ml, respectively). A trend of increased susceptibility
of C. glabrata to fluconazole was noted over the three-year period. The percentage of C. glabrata isolates sus-
ceptible to fluconazole increased from 48% in 1997 to 84% in 1999, and MIC50s decreased from 16 to 4 g/ml.
A similar trend was documented in both the Americas (57 to 84% susceptible) and Europe (22 to 80% sus-
ceptible). Some geographic differences in susceptibility to triazole were observed with Canadian isolates gen-
erally more susceptible than isolates from the United States and Europe. These observations suggest suscep-
tibility patterns and trends among yeast isolates from BSI and raise additional questions that can be answered
only by continued surveillance and clinical investigations of the type reported here (SENTRY Program).
It is now well accepted that antimicrobial resistance is an
important concern with respect to virtually all major groups of
pathogenic microorganisms, including viruses, bacteria, para-
sites, and fungi. Numerous approaches to control this ever-
increasing problem have been suggested (2, 10, 27, 30). One
critical component in every suggested mode of intervention is
the need for continued monitoring or surveillance of resistance
on a global scale. Surveillance of antibacterial resistance is now
being conducted by several different groups with the common
goal of providing accurate data for use in the development of
empiric treatment recommendations, for the development of
guidelines and policies for appropriate antimicrobial utiliza-
tion, for assessing the progress and effectiveness of various
intervention efforts, and for tailoring or improving antimi-
crobial susceptibility testing (AST) methods and resistance
screening (2, 10, 13).
Although innate or acquired resistance to available antifun-
gal agents is now recognized among pathogenic fungi, partic-
ularly the Candida species, the true extent of the resistance
problem among fungi causing hematogenously disseminated or
bloodstream infections (BSI) is largely unknown. Among the
several active antimicrobial resistance surveillance programs
now in existence, the SENTRY Antimicrobial Surveillance Pro-
gram is the only system that monitors BSI due to Candida spp.
as well as bacterial species (5, 6, 13, 22). The SENTRY Pro-
gram is comprehensive, longitudinal, and global in scope and
utilizes a central laboratory concept to monitor trends in mi-
crobial spectra and resistance in 74 sentinel sites in 22 nations.
Since 1997, one of the important objectives of the SENTRY
Program has been the study of the frequency of occurrence and
antifungal resistance among species of Candida causing BSI in
the United States, Canada, Latin America, and Europe (5, 16,
21, 22). The rank order of occurrence and resistance profiles of
the various species of Candida causing BSI is important in
establishing empiric treatment protocols and in judging the
potential impact of newer antifungal agents. Using this ap-
proach, a number of important and unusual resistance pheno-
types have been detected over the three-year period from 1997
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to 1999 (5, 16, 21, 22). Examples that will be discussed herein
include Candida glabrata isolates resistant to amphotericin B,
Candida krusei isolates resistant to amphotericin B, flucon-
azole, and 5-fluorocytosine (5FC), cross-resistance to estab-
lished and investigational triazoles, and decreased resistance
to fluconazole among C. glabrata isolates and to itraconazole
among Candida tropicalis isolates. Species differences occur-
ring among different geographic regions have also been noted.
MATERIALS AND METHODS
Study design. The SENTRY Program was established in 1997 to monitor the
predominant pathogens and antimicrobial resistance patterns of nosocomial and
community-acquired infections via a broad network of sentinel hospitals catego-
rized by geographic location and size (5, 16, 21, 22). The present report focuses
on BSI due to Candida spp. from U.S., Canadian, Latin American, and European
sites. BSI due to Candida spp. were reported from 32 monitored medical centers
in the United States, 23 in Europe, 9 in Latin America, and 7 in Canada over the
three-year period from January 1997 through December 1999.
Each participant hospital contributed results (organism identification, date of
isolation, and hospital location) for consecutive blood culture isolates (one iso-
late per patient) of Candida spp. judged to be clinically significant by local
criteria, detected in each calendar month during the study period. All isolates
were stored on agar slants and sent on a regular basis to the University of Iowa
College of Medicine (Iowa City) for storage and further characterization by
reference identification and susceptibility testing (14, 29).
Organism identification. All fungal blood culture isolates were identified at
the participating institutions by the routine method in use at each laboratory.
Upon receipt at the University of Iowa, the isolates were subcultured onto potato
dextrose agar (Remel, Lenexa, Kans.) and CHROMagar Candida medium (Har-
dy Laboratories, Santa Maria, Calif.) to ensure viability and purity. Confirmation
of species identification was performed with Vitek and API products (bio-
Merieux, St. Louis, Mo.) as recommended by the manufacturer or by conven-
tional methods as required (29). Isolates were stored as suspensions in water or
on agar slants at an ambient temperature until needed.
Susceptibility testing. Antifungal susceptibility testing of isolates of Candida
spp. was performed by the reference broth microdilution method described by
the NCCLS (14). Susceptibility of isolates to amphotericin B was determined
using Etest (AB BIODISK, Sonia, Sweden) and RPMI 1640 agar with 2%
glucose (Remel, Lenexa, Kans.) as described previously (17). Standard powders
of fluconazole (Pfizer, Inc., New York, N.Y.), voriconazole (Pfizer), ravucon-
azole (Bristol-Myers Squibb, Wallingford, Conn.), itraconazole (Janssen, Beerse,
Belgium), and 5-fluorocytosine (5FC; Sigma, St. Louis, Mo.) were obtained from
their respective manufacturers. Following incubation at 35°C for 48 h, the MICs
of fluconazole, voriconazole, ravuconazole, itraconazole, and 5FC were read as
the lowest concentration at which a prominent decrease in turbidity relative to
the growth control well was observed (14). Amphotericin B MICs determined by
Etest were read after 48 h of incubation at 35°C and were determined to be at
100% inhibition of growth where the border of the elliptical inhibition zone
intercepted the scale on the strip edge (17). Quality control (QC) was ensured by
testing the NCCLS (14)-recommended strains, Candida krusei ATCC 6258 and
Candida parapsilosis ATCC 22019.
Interpretive criteria for susceptibility to fluconazole (susceptibility breakpoint,
MIC of 8 g/ml), itraconazole (susceptible, MIC of 0.12 g/ml), and 5FC
(susceptible, MIC of 4 g/ml) were those published by Rex et al. (23) and the
NCCLS (14). These breakpoints apply to all Candida spp. (including C. glabrata)
with the exception of C. krusei, which is considered inherently resistant to flu-
conazole regardless of the MIC obtained (14). Interpretive criteria have not yet
been defined for amphotericin B; however, because the study of Nguyen et al.
(15) suggested that amphotericin B MICs of 1 g/ml may indicate clinically
resistant isolates of Candida spp., we determined the percentage of isolates
inhibited by 1 g/ml to be susceptible in this surveillance study. Likewise, the
investigational triazoles, voriconazole and ravuconazole, have not been assigned
interpretive breakpoints. For purposes of comparison and because preliminary
pharmacokinetic data indicate that achievable serum levels for these agents may
range from 2 to 6 g/ml depending on the dosing regimen (26), we have em-
ployed a susceptibility breakpoint of 1 g/ml for both voriconazole and ravu-
conazole.
Statistical analysis. Comparison of species distribution and/or MIC distribu-
tion by other factors (e.g., year, geographic region) were made using the chi-
square test with Yates’ correction for categorical variables and the Wilcoxon
rank sum test for ordinal variables (MICs). All reported P values are two-tailed.
RESULTS AND DISCUSSION
During the 36-month study period, a total of 1,184 BSI
isolates (episodes) of Candida spp. were submitted by 71 study
centers in the United States (32 centers, 589 isolates), Canada
(7 centers, 161 isolates), Latin America (9 centers, 132 iso-
lates), and Europe (23 centers, 302 isolates). These isolates
accounted for 3% of all BSI isolates (bacterial and fungal)
from nosocomial and community-acquired infections and 9%
of nosocomial BSI (bacterial and fungal) isolates submitted by
SENTRY participants from 1997 to 1999. Candida spp. was the
fourth-most-common nosocomial BSI isolate category, pre-
ceded only by Staphylococcus aureus, coagulase-negative staph-
ylococci, and enterococci (data not shown). The original iden-
tification assigned by the participating center was confirmed
for 97% of the isolates submitted. Among the 1,184 BSI, 75%
were nosocomial (detected more than 48 h after admission to
a hospital), and 50% occurred in patients hospitalized in an
intensive care unit (ICU).
The frequencies of BSI due to the various species of Can-
dida in each country over the three-year period are presented
in Table 1. Of the 1,184 yeast BSI whose organisms were iden-
tified, 55% were due to C. albicans, 15% were due to C. gla-
brata, 15% were due to C. parapsilosis, 9% were due to C. tropi-
calis, and 6% were due to miscellaneous Candida spp. The
rank order of the various species differed according to geo-
graphic location. C. albicans was the predominant species in all
four geographic areas, accounting for 45 to 60% of all BSI.
C. glabrata was the second-most-common species in the United
States (21% of BSI; P  0.01 compared to prevalence in other
geographic areas) but ranked either third or fourth in the other
areas. In contrast to the case in the United States, C. glabrata
was very uncommon in Latin America (6% of all isolates; P 
0.001 compared to U.S. results). C. parapsilosis was the second-
most-common Candida species, causing BSI in Latin America
(25%; P  0.001 compared to U.S. results), Canada (16%),
and Europe (19%; P 0.001 compared to U.S. results). C. kru-
sei was encountered infrequently (1 to 2%) in all geographic
areas.
The rank order of species in all four geographic areas was
relatively stable over the three-year period. However, the over-
all rank order may not represent the situation in individual
TABLE 1. Species distribution of Candida bloodstream isolates:
SENTRY Program, 1997 to 1999
Species
% Isolates by geographic areaa
U.S.
(n  589)
Canada
(n  161)
Latin America
(n  132)
Europe
(n  302)
C. albicans 55 60 45 58
C. glabrata 21b 12 6 10
C. parapsilosis 11 16 25c 19c
C. tropicalis 9 6 16d 7
C. krusei 2 2 1 1
Candida spp. 2 4 7 5
a n, no. tested. U.S., United States.
b P  0.01 compared to prevalence in other geographic areas.
c P  0.001 compared to prevalence in the United States.
d P  0.03 compared to prevalence in other geographic areas.
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medical centers. The percentages of candidemias due to C. al-
bicans varied considerably among the individual participating
study sites (Table 2). C. albicans was clearly the predominat-
ing species in certain medical centers, accounting for 70% of
candidemias in Turkey-3 (73%), France-3 (73%), Italy-2
(88%), Switzerland (80%), Turkey-2 (74%), New Mexico (82%),
New York-3 (70%), Texas-2 (83%), Nova Scotia (71%), and
Ontario (85%) (a numerical suffix indicates a particular site
within a state or country). In contrast, C. albicans accounted
for 40% of BSI in Germany-1 (21%), Spain-2 (29%), Mas-
sachusetts (38%), New York-2 (37%), North Carolina (35%),
and Brazil-1 (24%).
These data demonstrate that although C. albicans may con-
tinue to play a dominant role as a cause of fungemia in many
centers, it has been supplanted by C. glabrata in certain U.S.
centers and by C. parapsilosis or C. tropicalis in some European
and Latin American centers. The reasons for such dramatic
differences in Candida species causing BSI remains specula-
tive, although the emergence of C. glabrata in certain centers
has been linked to utilization of fluconazole prophylaxis (1, 3),
and infections attributable to C. parapsilosis are often associ-
ated with hyperalimentation and breaches of catheter care and
of infection control practice (12, 18, 19, 22).
In vitro susceptibility results for the 1,184 isolates tested with
fluconazole, ravuconazole, and voriconazole are shown in Ta-
ble 3. Fluconazole was active in all regions, with 90 to 98% of
isolates susceptible (S) to a drug concentration of 8 g/ml.
Isolates from Canada (concentration at which 90% of the iso-
lates are inhibited [MIC90], 4 g/ml; 96% S) and Latin Amer-
ica (MIC90, 4 g/ml; 98% S) were more susceptible than
those from the United States (MIC90, 16; 90% S) and Europe
(MIC90, 8 g/m; 90% S) due to the presence of resistance
(MIC, 64 g/ml) among C. glabrata isolates in the latter two
regions. Both ravuconazole (MIC90, 0.12 to 0.5 g/m; 98 to
99% S) and voriconazole (MIC90, 0.12 to 0.25 g/ml; 98 to
99% S) were considerably more potent than fluconazole
against isolates from all four geographic areas.
Table 4 summarizes the in vitro susceptibilities to flucon-
azole, ravuconazole, and voriconazole for the individual spe-
cies of Candida from all areas stratified by year. Isolates of
C. albicans, C. parapsilosis, and C. tropicalis were all highly sus-
ceptible (97 to 100%) to fluconazole and the investigational tri-
azoles. Interestingly, C. glabrata demonstrated a trend towards
increased susceptibility to fluconazole from 1997 (MIC50,
16 g/ml; 48% S) to 1999 (MIC50, 4 g/ml; 83% S; P  0.004
for the trend). This trend was apparent in both the Americas
and Europe (data not shown). Reasons for this trend are un-
clear but may be related to more appropriate uses and im-
proved dosing of fluconazole (3). Both ravuconazole and vori-
conazole were quite active (MIC50, 0.12 to 0.5 g/ml; 97 to
100% S) against both C. glabrata and C. krusei. Notably, no
trend towards increased resistance to any of the agents tested
was observed over the three-year period.
TABLE 2. Geographic location and percent of Candida
bloodstream infections attributable to C. albicans
(SENTRY Program, 1997 to 1999)
Locationa No. of isolates % C. albicans
Europe
Turkey-1 11 73
Turkey-2 23 74
France-1 11 55
France-3 11 73
Germany-1 19 21
Italy-1 35 66
Italy-2 17 88
Portugal 39 46
Spain-1 21 67
Spain-2 14 29
Switzerland 15 80
United States
Indiana 31 48
Arizona 13 62
New Mexico 22 82
Chicago 58 52
Iowa 24 58
Massachusetts 29 38
New York-1 29 41
New York-2 38 37
New York-3 44 70
California-1 17 53
California-2 25 56
Washington 17 47
Missouri 64 52
Texas-1 16 50
Texas-2 12 83
Texas-3 12 58
Kentucky 17 59
North Carolina 17 35
Virginia 44 68
Utah 12 58
Canada
Alberta 26 54
Manitoba 37 62
Nova Scotia 34 71
Ontario 13 85
Quebec 35 51
Latin America
Argentina 14 43
Brazil-1 29 24
Brazil-2 24 50
Brazil-3 35 54
Chile 14 64
a Only those sites with 10 BSI isolates are shown. Where results were avail-
able for more than one site within a state or country, the numerical suffix
indicates the individual site.
TABLE 3. Activities of fluconazole and investigational antifungal agents against 1,184 BSI isolates of Candida spp.
from four geographic regions (SENTRY Program, 1997 to 1999)
Antifungal
agent
MIC (g/ml) and % susceptible by countrya
U.S. (n  589) Canada (n  161) Latin America (n  132) Europe (n  302)
50/90% % S 50/90% % S 50/90% % S 50/90% % S
Fluconazole 0.25/16 90 0.25/4 96 0.25/4 98 0.25/8 90
Ravuconazole 0.015/0.25 98 0.015/0.12 99 0.015/0.25 99 0.007/0.5 98
Voriconazole 0.015/0.25 98 0.015/0.12 99 0.015/0.12 99 0.007/0.25 99
a n, no. tested. U.S., United States. % S, percent susceptible at a MIC of 8 g/ml (fluconazole) or 1 g/ml (all other agents).
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Although it is not shown in Table 4, C. tropicalis demon-
strated a trend towards increased susceptibility to itraconazole
(susceptible MIC,0.12 g/ml) from 1997 (MIC50, 0.25 g/ml;
48% S) to 1999 (MIC50, 0.06 g/ml; 82% S; P  0.005). A
similar shift was not observed with itraconazole and any other
species. More than 97% of C. tropicalis isolates were inhibited
by 1 g/ml of itraconazole. This trend is similar to the shift
observed with C. glabrata and fluconazole and bears watching.
Despite excellent activity against the vast majority of Can-
dida BSI isolates, cross-resistance was observed with both ra-
vuconazole and voriconazole when they were tested against 12
isolates of C. albicans that were resistant to both fluconazole
(MIC, 64 g/ml) and itraconazole (MIC, 1 g/ml) (data
not shown) (20). Such isolates are quite rare among those
organisms causing BSI but are indicative of the potential for
development of complete class resistance against the azoles if
fluconazole or itraconazole are misused.
Fluconazole was equally active against Candida BSI isolates
from patients hospitalized in the ICU (93% S) and the non-
ICU (92% S) setting (Table 5). This finding was in contrast to
that observed with bacterial BSI isolates, where ICU-related
infection isolates were generally less susceptible to antimicro-
bial agents than non-ICU strains (5, 7, 9). Similarly, no differ-
ence in susceptibility to six different antifungal agents was
noted between nosocomial and community-acquired BSI iso-
lates of Candida spp. Again, this observation was distinctly
different from the experience with bacterial BSI isolates, where
nosocomial strains were almost always more resistant to anti-
microbial agents than community-acquired strains (5). Nota-
bly, only 70 to 72% of Candida spp. were found to be suscep-
tible to amphotericin B at concentrations of 1 g/ml when
tested on RPMI agar using Etest (17). The Etest method has
been shown to be the most sensitive and reliable method for
identifying strains of Candida with clinically significant resis-
tance to amphotericin B (4, 17, 28).
Further examination of selected species susceptibility to am-
photericin B revealed striking differences when the isolates
were tested on RPMI agar using Etest (Table 6). As has been
noted previously, approximately 95% of C. albicans isolates
were inhibited by 1 g/ml of amphotericin B compared to
only 41% of C. glabrata isolates and 0% of C. krusei isolates
(P 0.01 for comparison of susceptibility by species) (8, 11, 15,
17, 24, 25). This in vitro data is consistent with the clinical
experience of breakthrough fungemias with C. glabrata and
C. krusei despite treatment with amphotericin B at standard
doses of 0.5 to 0.6 mg/kg of body weight/day (25). Current
Infectious Diseases Society of America (IDSA) treatment
guidelines recommend higher doses of amphotericin B (1 mg/
kg/day) when treating C. glabrata and C. krusei fungemia (25).
Thus, both C. glabrata and C. krusei may be relatively resistant
to both azoles and polyenes and could pose significant thera-
peutic problems in the future if such strains proliferate. C. kru-
sei is also often resistant (70%) to 5FC as well (20).
Summary and conclusions. This most recent analysis of data
from the SENTRY Antimicrobial Surveillance Program con-
firms the fact that Candida spp. remain the fourth-most-com-
TABLE 4. In vitro susceptibilities of blood stream infection isolates of Candida spp. to fluconazole and investigational antifungal agents
(SENTRY Program, 1997 to 1999)
Species (no. tested) Antifungal agent
MIC (g/ml) and % susceptible by year
1997 1998 1999
50/90% % Sa 50/90% % Sa 50/90% % Sa
C. albicans (658) Fluconazole 0.25/0.5 99 0.25/0.5 98 0.25/0.25 100
Ravuconazole 0.007/0.03 99 0.007/0.03 99 0.007/0.015 100
Voriconazole 0.015/0.06 98 0.007/0.03 99 0.007/0.015 100
C. glabrata (180) Fluconazoleb 16/32 48 8/16 63 4/16 83
Ravuconazole 0.25/1 92 0.25/1 95 0.12/1 94
Voriconazole 0.25/1 91 0.25/1 95 0.12/0.5 96
C. parapsilosis (179) Fluconazole 0.5/2 100 0.5/1 98 0.5/1 100
Ravuconazole 0.015/0.06 100 0.015/0.06 100 0.015/0.06 100
Voriconazole 0.03/0.12 100 0.015/0.06 100 0.015/0.03 100
C. tropicalis (104) Fluconazole 1/2 100 0.5/1 100 0.5/2 97
Ravuconazole 0.03/0.12 100 0.03/0.12 100 0.015/0.12 97
Voriconazole 0.06/0.12 100 0.03/0.12 100 0.03/0.12 97
C. krusei (20) Fluconazole 32/—c 0 32/— 0 16/— 0
Ravuconazole 0.25/— 100 0.25/— 100 0.25/— 100
Voriconazole 0.5/— 100 0.25/— 100 0.25/— 100
a % S, percent susceptible at a MIC of 8 g/ml (fluconazole) or 1 g/ml (all other agents).
b P  0.0004 for trend in susceptibility by year.
c —, MIC90 not calculated because 10 isolates were identified during the year.
TABLE 5. Activity of fluconazole against Candida blood
stream isolates from ICU and non-ICU settings
(SENTRY Program, 1997 to 1999)
Setting
(no. tested)
Cumulative % occurrence at MIC (g/ml) of:
0.12 0.25 0.5 1 2 4 8 16 32 64
ICU (393) 18.8 59.0 70.7 77.1 83.7 88.8 92.9 97.7 99.0 100.0
Non-ICU (402) 12.7 49.3 68.4 76.4 82.1 87.6 91.5 95.5 97.0 100.0
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mon cause of nosocomial BSI (7, 18). Although C. albicans
continues to account for approximately one-half of candide-
mias world-wide, its frequency may vary widely from institution
to institution, emphasizing the need for yeast species identifi-
cation of BSI isolates in individual institutions. Different, and
as yet unknown, factors may influence the species distribution
of Candida spp. causing BSI. The prominence of C. glabrata in
the United States as opposed to the other regions in the SEN-
TRY Program may be influenced by extensive utilization of
fluconazole at relatively low doses (400 mg/day), enhancing
selection of this species (3). In contrast, the frequent isolation
of C. parapsilosis in other regions may reflect issues of subop-
timal catheter care and infection control (1, 12).
Importantly, no increase in resistance to azoles was observed
in any of the geographic regions over the three-year study
period. The trend towards decreased resistance to fluconazole
among C. glabrata isolates and to itraconazole among C. tropi-
calis isolates is interesting and will require further investigation
to determine the factors behind these observations. Although
there is some evidence in the literature that both C. glabrata
and C. krusei may be relatively resistant to amphotericin B (15,
17, 24, 25), the application of the Etest to a large international
collection of Candida spp., such as the SENTRY Program
collection, provides information suggesting that elevated MICs
of drugs for these species may be more common than antici-
pated.
Additional data, not previously available, indicate that in con-
trast to the experience with antibacterial agents, no difference
in susceptibility to the existing antifungal agents was observed
among ICU versus non-ICU isolates and nosocomial versus
community-acquired strains of Candida spp. This may reflect
the fact that to the best of our knowledge Candida spp. lack
mobile resistance genes and thus require considerably different
circumstances and exposures in order to develop high levels of
resistance compared to bacterial pathogens.
Finally, although the new triazoles (ravuconazole and vori-
conazole) display improved potency compared to fluconazole,
it is apparent that cross-resistance to these agents may be ob-
served among the rare BSI isolates of Candida that are resis-
tant to both fluconazole and itraconazole. These observations
suggest certain susceptibility patterns and trends among yeast
isolates from BSI and raise additional questions that can be
answered only by continued surveillance and clinical investiga-
tions of the type reported here (SENTRY Program).
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